Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New way to make malaria medicine also first step in finding new antibiotics

30.09.2008
University of Illinois microbiology professor William Metcalf and his collaborators have developed a way to mass-produce an antimalarial compound, potentially making the treatment of malaria less expensive.

Metcalf set out to understand how this compound, one of a group known as phosphonates, is made in nature by bacteria. He was interested in that process partly because some phosphonates have antibiotic properties. Recently, Metcalf and his lab successfully identified and sequenced the genes and identified the processes by which bacteria make this particular phosphonate compound (FR900098).

His results are reported in the August 25 issue of Chemistry & Biology.

Although the compound has already been chemically synthesized, that is a costly process. By knowing how this phosphonate is biosynthesized, it can now be inexpensively mass-produced by harnessing the cellular machinery of bacteria.

"Malaria is a problem in Third World countries that can least afford expensive medicines, and many antibiotics are expensive," Metcalf said.

Efforts are already underway by Metcalf's colleague, chemical engineering professor Huimin Zhao, to engineer E. coli strains to overproduce FR900098, which can then be harvested for medicine.

In addition, says Metcalf, knowing the genes and understanding the pathway that bacteria use to make this antimalarial means the genes can be manipulated to make the compound even more effective against the malaria parasite while remaining harmless to people.

This effort to help treat malaria is just one facet of a major undertaking to find new antibiotics. Last year Metcalf and his colleagues at the U. of I.'s Institute for Genomic Biology, chemistry professor Wilfred van der Donk, Zhao, chemistry professor Neil Kelleher, and biochemistry professor Satish Nair, received a $7.3 million grant from the National Institutes of Health to investigate just this. Jo Handelsman of the University of Wisconsin rounds out the research team.

The need for new antibiotics is at an all-time high because multi-drug resistant bacteria are appearing even outside hospital settings. Consequently, infections that used to be easily curable have become more difficult to treat. For example, tuberculosis has become so resistant to antibiotics that soon "they'll send you to Arizona to drier air, like they did before they had antibiotics," Metcalf said.

In the case of malaria, the World Health Organization's "World Malaria Report 2008" estimates that "half of the world's population is at risk of malaria, and an estimated 247 million cases led to nearly 881,000 deaths in 2006."

Resistance to classic drugs such as chloroquine and sulphadoxine-pyrimethamine is on the rise, and mosquitoes also are developing resistance to insecticides.

"In my opinion malaria is the biggest single infectious disease problem in the world," Metcalf said.

The World Health Organization now advocates treating malaria with multiple antibiotics simultaneously, to combat the parasites' ability to develop resistance.

"In an infection, the chances are high that one in 10 million parasites in the patient's body will become resistant to a given drug," Metcalf said. "Now, if a patient takes a second drug simultaneously, one in 10 million parasites also becomes resistant to that drug. However, the odds that the same parasite will develop a resistance to both drugs is one in 10 million times one in 10 million, or 10 to the 14th."

This combination therapy approach is how HIV-AIDS, tuberculosis and other diseases are now treated. In the case of malaria, combination therapy both cures the patient and prevents wider infection, since an uninfected mosquito can acquire (and spread) the parasite by biting an infected person. But in many places where malaria is endemic, this approach is not used, in part because of the cost of medicine.

By making medicines more affordable it increases the chances that they will be used in the most effective way possible, that is to say, in combination with one another.

Metcalf became interested in anti-malarial medicine because of his interest in phosphonates, molecules that contain direct chemical bonds between carbon and phosphorus atoms (as opposed to the carbon-to-oxygen-to-phosphorus bonds that are found in most biological molecules containing phosphorus). As a doctoral student he characterized how microbes metabolized phosphonic acid in glyphosate, known commercially as RoundUp. He began to wonder where this class of compounds comes from and how it is made in nature.

In addition to sequencing the genes that make FR900098, Metcalf and his colleagues are focused on determining just how many naturally occurring phosphonic acids, or phosphonates, there are that have useful antibiotic, antifungal or anti-cancer properties.

The scientific community has known since the 1970s that bacteria routinely produce these types of phosphonates, in a kind of natural biological warfare.

"If you are a bacterium and you can kill off your neighbors you're better off yourself. It's kill or be killed," Metcalf said.

However, until now no one has done a systematic search for phosphonates in nature. Phosphonates work by disrupting biological pathways that use phosphate esters and organic acids. Each phosphonate disrupts a particular pathway. For example, FR900098 inhibits the pathway that creates isoprenoids, building blocks for important cellular components. When the parasites that cause malaria were discovered by others to have a pathway that FR900098 could disrupt, researchers saw a way to put the compound to good use. That same biosynthetic pathway does not exist in animals, which have a different way of making isoprenoids.

Understanding these pathways "opens the door to finding other antibiotics in this class of compounds. The more we can understand about these pathways the better we can find unknown phosphonates with antibiotic properties," Metcalf said.

His lab has developed a directed strategy to clone and sequence the genes that are required for phosphonate synthesis in bacteria, making the search efficient and exhaustive. Metcalf is optimistic that he and others will be able to mine phosphonates for other antibiotics.

"We've grown up in the Golden Age of antibiotics," he said. "But now kids can come home with an infection in their arm that can't be treated. And what happens if you can't treat it? You may have to amputate the arm. This is no joke; we better find new treatments."

Melissa Edwards | EurekAlert!
Further information:
http://www.illinois.edu

More articles from Life Sciences:

nachricht New study finds distinct microbes living next to corals
22.05.2019 | Woods Hole Oceanographic Institution

nachricht Summit charts a course to uncover the origins of genetic diseases
22.05.2019 | DOE/Oak Ridge National Laboratory

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

Im Focus: A step towards probabilistic computing

Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future

When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...

Im Focus: Recording embryonic development

Scientists develop a molecular recording tool that enables in vivo lineage tracing of embryonic cells

The beginning of new life starts with a fascinating process: A single cell gives rise to progenitor cells that eventually differentiate into the three germ...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Summit charts a course to uncover the origins of genetic diseases

22.05.2019 | Life Sciences

New study finds distinct microbes living next to corals

22.05.2019 | Life Sciences

Stellar waltz with dramatic ending

22.05.2019 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>